DE3930168A1 - Pharmaceutical compsn. contg. colestyramine to reduce lipid - in micro:tablet form levels without unpleasant taste - Google Patents
Pharmaceutical compsn. contg. colestyramine to reduce lipid - in micro:tablet form levels without unpleasant tasteInfo
- Publication number
- DE3930168A1 DE3930168A1 DE3930168A DE3930168A DE3930168A1 DE 3930168 A1 DE3930168 A1 DE 3930168A1 DE 3930168 A DE3930168 A DE 3930168A DE 3930168 A DE3930168 A DE 3930168A DE 3930168 A1 DE3930168 A1 DE 3930168A1
- Authority
- DE
- Germany
- Prior art keywords
- colestyramine
- micro
- contg
- microtablets
- tablet form
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Withdrawn
Links
- 229920001268 Cholestyramine Polymers 0.000 title claims abstract description 18
- KNDHRUPPBXRELB-UHFFFAOYSA-M [4-[3-(4-ethylphenyl)butyl]phenyl]-trimethylazanium;chloride Chemical compound [Cl-].C1=CC(CC)=CC=C1C(C)CCC1=CC=C([N+](C)(C)C)C=C1 KNDHRUPPBXRELB-UHFFFAOYSA-M 0.000 title claims description 17
- 229960001678 colestyramine Drugs 0.000 title claims description 17
- 150000002632 lipids Chemical class 0.000 title abstract 2
- 239000011230 binding agent Substances 0.000 claims abstract description 10
- 239000000825 pharmaceutical preparation Substances 0.000 claims description 6
- 229940127557 pharmaceutical product Drugs 0.000 claims description 6
- 239000003524 antilipemic agent Substances 0.000 claims description 5
- 239000000203 mixture Substances 0.000 claims description 4
- 238000009472 formulation Methods 0.000 claims description 3
- 239000000654 additive Substances 0.000 claims description 2
- 238000005469 granulation Methods 0.000 abstract description 3
- 230000003179 granulation Effects 0.000 abstract description 3
- 239000000314 lubricant Substances 0.000 abstract description 2
- 239000008280 blood Substances 0.000 abstract 1
- 210000004369 blood Anatomy 0.000 abstract 1
- 239000002552 dosage form Substances 0.000 abstract 1
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 6
- 230000000694 effects Effects 0.000 description 6
- HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 description 6
- 239000002245 particle Substances 0.000 description 6
- 238000000034 method Methods 0.000 description 4
- 239000008187 granular material Substances 0.000 description 3
- 150000002500 ions Chemical class 0.000 description 3
- 235000019359 magnesium stearate Nutrition 0.000 description 3
- 239000000377 silicon dioxide Substances 0.000 description 3
- 235000012239 silicon dioxide Nutrition 0.000 description 3
- KFZMGEQAYNKOFK-UHFFFAOYSA-N Isopropanol Chemical compound CC(C)O KFZMGEQAYNKOFK-UHFFFAOYSA-N 0.000 description 2
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 2
- 229920000168 Microcrystalline cellulose Polymers 0.000 description 2
- 239000001913 cellulose Substances 0.000 description 2
- 229920002678 cellulose Polymers 0.000 description 2
- 235000010980 cellulose Nutrition 0.000 description 2
- 230000006378 damage Effects 0.000 description 2
- 239000008101 lactose Substances 0.000 description 2
- 229920000609 methyl cellulose Polymers 0.000 description 2
- 239000001923 methylcellulose Substances 0.000 description 2
- 235000010981 methylcellulose Nutrition 0.000 description 2
- 235000019813 microcrystalline cellulose Nutrition 0.000 description 2
- 239000008108 microcrystalline cellulose Substances 0.000 description 2
- 229940016286 microcrystalline cellulose Drugs 0.000 description 2
- LNAZSHAWQACDHT-XIYTZBAFSA-N (2r,3r,4s,5r,6s)-4,5-dimethoxy-2-(methoxymethyl)-3-[(2s,3r,4s,5r,6r)-3,4,5-trimethoxy-6-(methoxymethyl)oxan-2-yl]oxy-6-[(2r,3r,4s,5r,6r)-4,5,6-trimethoxy-2-(methoxymethyl)oxan-3-yl]oxyoxane Chemical compound CO[C@@H]1[C@@H](OC)[C@H](OC)[C@@H](COC)O[C@H]1O[C@H]1[C@H](OC)[C@@H](OC)[C@H](O[C@H]2[C@@H]([C@@H](OC)[C@H](OC)O[C@@H]2COC)OC)O[C@@H]1COC LNAZSHAWQACDHT-XIYTZBAFSA-N 0.000 description 1
- 229920000663 Hydroxyethyl cellulose Polymers 0.000 description 1
- 239000004354 Hydroxyethyl cellulose Substances 0.000 description 1
- 208000035150 Hypercholesterolemia Diseases 0.000 description 1
- 235000021355 Stearic acid Nutrition 0.000 description 1
- 150000001450 anions Chemical class 0.000 description 1
- 210000000941 bile Anatomy 0.000 description 1
- 239000003613 bile acid Substances 0.000 description 1
- 239000003795 chemical substances by application Substances 0.000 description 1
- 229920001577 copolymer Polymers 0.000 description 1
- 239000003814 drug Substances 0.000 description 1
- 239000002706 dry binder Substances 0.000 description 1
- 238000001035 drying Methods 0.000 description 1
- 235000019447 hydroxyethyl cellulose Nutrition 0.000 description 1
- -1 hydroxypropyl Chemical group 0.000 description 1
- 239000001866 hydroxypropyl methyl cellulose Substances 0.000 description 1
- 235000010979 hydroxypropyl methyl cellulose Nutrition 0.000 description 1
- 229920003088 hydroxypropyl methyl cellulose Polymers 0.000 description 1
- UFVKGYZPFZQRLF-UHFFFAOYSA-N hydroxypropyl methyl cellulose Chemical compound OC1C(O)C(OC)OC(CO)C1OC1C(O)C(O)C(OC2C(C(O)C(OC3C(C(O)C(O)C(CO)O3)O)C(CO)O2)O)C(CO)O1 UFVKGYZPFZQRLF-UHFFFAOYSA-N 0.000 description 1
- QIQXTHQIDYTFRH-UHFFFAOYSA-N octadecanoic acid Chemical compound CCCCCCCCCCCCCCCCCC(O)=O QIQXTHQIDYTFRH-UHFFFAOYSA-N 0.000 description 1
- OQCDKBAXFALNLD-UHFFFAOYSA-N octadecanoic acid Natural products CCCCCCCC(C)CCCCCCCCC(O)=O OQCDKBAXFALNLD-UHFFFAOYSA-N 0.000 description 1
- 230000002085 persistent effect Effects 0.000 description 1
- 239000001267 polyvinylpyrrolidone Substances 0.000 description 1
- 229920000036 polyvinylpyrrolidone Polymers 0.000 description 1
- 235000013855 polyvinylpyrrolidone Nutrition 0.000 description 1
- 238000002360 preparation method Methods 0.000 description 1
- 230000001105 regulatory effect Effects 0.000 description 1
- 239000008117 stearic acid Substances 0.000 description 1
- 239000000454 talc Substances 0.000 description 1
- 229910052623 talc Inorganic materials 0.000 description 1
- 229920002554 vinyl polymer Polymers 0.000 description 1
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/74—Synthetic polymeric materials
- A61K31/785—Polymers containing nitrogen
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
- A61K31/19—Carboxylic acids, e.g. valproic acid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
- A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2072—Pills, tablets, discs, rods characterised by shape, structure or size; Tablets with holes, special break lines or identification marks; Partially coated tablets; Disintegrating flat shaped forms
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Emergency Medicine (AREA)
- Medicinal Preparation (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
Description
Die Erfindung betrifft ein pharmazeutisches Erzeugnis, das Colestyramin als Lipidsenker enthält und das in einer zur Anwendung verbesserten Form vorliegt.The invention relates to a pharmaceutical product, colestyramine contains as a lipid-lowering agent and that in an improved form for use is present.
Colestyramin ist der internationale Freiname für das Chlorid eines quartäre Ammoniumgruppen enthaltenden Styrol-Divinylbenzol-Copolymerisats. Colestyramin ist als Anionenaustauscher zur Bindung von Gallensäuren bei Gallenstauung und bei Hypercholesterinämie wirksam. Bei Anwendung als Lipidsenker muß man relativ große Dosismengen einsetzen, die beispiels weise bei etwa 4 g liegen können. Das ist insofern unangenehm, als das Colestyramin in Form seesandgroßer, wasserunlöslicher Ionenaustauscher partikel vorliegt und in Wasser angerührt werden muß. Nach der Einnahme verbleibt ein nachhaltig unangenehm sandiger Geschmack im Mund, der bisweilen auch als Treibsandeffekt bezeichnet wird und sich als ausgesprochen Patienten-unfreundlich erweist.Colestyramine is the international free name for a chloride quaternary ammonium group-containing styrene-divinylbenzene copolymer. Colestyramine acts as an anion exchanger to bind bile acids Bile congestion and effective in hypercholesterolemia. When used as Lipid-lowering agents must be used in relatively large amounts, for example may be around 4 g. This is uncomfortable in that it is Colestyramine in the form of sea sand-sized, water-insoluble ion exchangers particle is present and must be mixed in water. After taking it a persistent, unpleasant sandy taste remains in the mouth is sometimes referred to as quicksand effect and as extremely patient-unfriendly.
Im Stand der Technik ist es bislang nicht gelungen, Colestyramin in eine Form zu bringen, die keinen Treibsandeffekt zeigt.So far, it has not been possible to use colestyramine in one Bring shape that shows no quicksand effect.
Der Erfindung liegt die Aufgabe zugrunde, ein pharmazeutisches Erzeugnis, enthaltend Colestyramin als Lipidsenker, bereitzustellen, das leicht einzunehmen ist und keinen Treibsandeffekt zeigt.The invention is based on the object of a pharmaceutical product, containing colestyramine as a lipid-lowering agent to provide that easily is to be taken and shows no quicksand effect.
Diese Aufgabe wird gelöst durch ein pharmazeutisches Erzeugnis, enthaltend Colestyramin als Lipidsenker, das in Form von Mikrotabletten vorliegt.This object is achieved by a pharmaceutical product containing Colestyramine as a lipid-lowering agent, which is in the form of microtablets.
Im Stand der Technik wurde bislang kein Versuch unternommen, das Colestyramin als Mikrotablette zu formulieren. Das dürfte darauf beruhen, daß man von vornherein damit rechnen mußte, daß die spherischen Ionen austauscherpartikel beim Preßvorgang so stark geschert oder deformiert würden, daß erhebliche Anteile des Ionenaustauschers nicht mehr wirksam wären. Mit einer derartigen ungewollten Zerstörung der Colestyramin partikel während des Verpreßvorgangs mußte man auch beim Arbeiten unter Zuhilfenahme üblicher Bindemittel und anderer Hilfsstoffe rechnen, da in jedem Falle die genannten Kräfte auf die Colestyraminpartikel einwirken.No attempt has so far been made in the prior art that Formulate colestyramine as a micro tablet. That should be because that one had to expect from the outset that the spherical ions exchanger particles so severely sheared or deformed during the pressing process would make that significant portions of the ion exchanger no longer effective would be. With such an unwanted destruction of colestyramine Particles during the pressing process were also required when working under Use conventional binders and other auxiliaries, because in in any case, the forces mentioned act on the colestyramine particles.
Die Mikrotabletten sind bevorzugt zylindrisch und weisen vorzugsweise eine Größe von 1 bis 4 mm (sowohl Höhe wie auch Durchmesser), insbesondere 2,0 bis 3,5 mm, auf. The microtablets are preferably cylindrical and preferably have one Size from 1 to 4 mm (both height and diameter), especially 2.0 up to 3.5 mm.
Es war um so überraschender, als erfindungsgemäß festgestellt wurde, daß die befürchtete Beschädigung der Colestyraminteilchen und damit der befürchtete Aktivitätsverlust beim Verpressen zu Mikrotabletten nicht eintraten. Die durch das Verpressen erhaltenen Mikrotabletten besitzen im wesentlichen dieselbe Aktivität wie die losen Colestyraminpartikel, sind jedoch frei vom unangenehmen Treibsandeffekt.It was all the more surprising when it was found according to the invention that the feared damage to the colestyramine particles and thus the feared loss of activity when compressed into microtablets occurred. The microtablets obtained by pressing have in are essentially the same activity as the loose colestyramine particles but free of the unpleasant quicksand effect.
Nach einer bevorzugten Ausführungsform enthält das pharmazeutische Erzeugnis in Form von Mikrotabletten auch ein Bindemittel. Beim Binde mittel kann es sich beispielsweise um die folgenden handeln:According to a preferred embodiment, the pharmaceutical contains Product in the form of microtablets also a binder. With the bandage medium can be, for example, the following:
Trockenbindemittel wie mikrokristalline Cellulose mit einem Rezepturanteil in den Mikrotabletten von 2 bis 20%, vorzugsweise 3 bis 8%. Mit dieser relativen Bindemittelmenge ist es möglich, handelsübliches, fein partikuläres Colestyramin direkt zu verpressen.Dry binders such as microcrystalline cellulose with a recipe content in the microtablets from 2 to 20%, preferably 3 to 8%. With this relative amount of binder, it is possible to commercially available, fine to inject particular colestyramine directly.
Alternativ kann die gewünschte Formulierung als Mikrotablette auch über den üblichen Weg der Granulierung hergestellt werden. Hierzu eignen sich als Bindemittel alle Cellulosederivate, die pharmazeutisch üblich sind, wie z. B. Methylcellulose, Hydroxypropylmethylcellulose, Hydroxyethyl cellulose. Die Granulierung erfolgt unter Einsatz pharmazeutisch üblicher Lösungen der Bindemittel. Gut geeignet als Granulierbindemittel ist auch Polyvinylkollidon, das ebenfalls in pharmazeutisch üblicher Weise in das Granulat eingearbeitet wird. Der Bindemittelanteil in den Granulaten beträgt umgerechnet auf den Trockengehalt 2 bis 10%, vorzugsweise 3 bis 6%.Alternatively, the desired formulation as a microtablet can also be used the usual way of granulation. Are suitable for this all cellulose derivatives which are customary in pharmacy as binders, such as B. methyl cellulose, hydroxypropyl methyl cellulose, hydroxyethyl cellulose. The granulation is carried out using standard pharmaceuticals Binder solutions. It is also very suitable as a granulating binder Polyvinyl collidone, which is also in the pharmaceutically usual manner in the Granules are incorporated. The proportion of binder in the granules converted to the dry content is 2 to 10%, preferably 3 to 6%.
Als weitere übliche Zusätze und Formulierungshilfsmittel kommen die folgenden in Betracht:As other common additives and formulation aids come consider the following:
Hilfsbindemittel wie z. B. Lactose, speziell eine der handelsüblichen
direkttablettierbaren Aufbereitungen
Fließregulierungsmittel wie z. B. hochdisperses Siliciumdioxid oder Talkum
und Schmiermittel wie z. B. Stearinsäure oder Magnesiumstearat.Auxiliary binders such as B. lactose, especially one of the commercially available direct-tablettable preparations
Flow regulating agents such as B. highly disperse silicon dioxide or talc and lubricants such. B. stearic acid or magnesium stearate.
Die Herstellung der Mikrotabletten erfolgt beispielsweise nach der Arbeitsweise der EP-A-1 66 315.The micro-tablets are manufactured, for example, according to Operation of EP-A-1 66 315.
Die Arbeitsweise zur Herstellung des erfindungsgemäßen pharmazeutischen Erzeugnisses ergibt sich aus nachfolgenden Beispielen, die zur weiteren Erläuterung der Erfindung dienen. The procedure for producing the pharmaceutical according to the invention Product results from the following examples, which for further Explanation of the invention serve.
13,5 kg Colestyramin wurden in einem pharmaüblichen Hochleistungsmischer (Lödige Druvatherm 50 l ohne Zerhackereinsatz) mit 675 g direkttablettier barer Lactose und 600 g mikrokristalliner Cellulose vermischt. Nach weiterer Zugabe von 75 g hochdispersem Siliciumdioxid und 150 g Magnesium stearat wurde erneut gemischt. Diese Preßmischung konnte problemlos zu Mikrotabletten mit 3,5 mm Durchmesser und gleicher Höhe bei einer Einzel masse von 30 mg verpreßt werden.13.5 kg of colestyramine were in a pharmaceutical high-performance mixer (Lödige Druvatherm 50 l without chopper insert) with 675 g direct tablet Lactose and 600 g of microcrystalline cellulose mixed. To further addition of 75 g of highly disperse silicon dioxide and 150 g of magnesium stearate was mixed again. This press mix was no problem Microtablets with 3.5 mm diameter and the same height for a single mass of 30 mg are pressed.
13,5 kg Colestyramin wurden in einem pharmaüblichen Hochleistungsmischer (Lödige Druvatherm 50 l) mit Zerhacker mit einer Lösung von 0,7 kg Poly vinylpyrrolidon (mittlere Molekularmasse 25 000) in 2,1 kg Isopropanol versetzt und durchgranuliert. Nach dem Trocknen in einem Hordentrocken schrank bei 50°C wurde über ein oszillierendes Sieb mit 0,8 mm Maschen weite gesiebt. Das Granulat wurde im Pharmamischer mit 70 g hochdispersem Siliciumdioxid und 70 g Magnesiumstearat vermischt. Die preßfertige Masse konnte problemlos zu Mikrotabletten mit 3 mm Durchmesser und gleicher Höhe bei einer Einzelmasse von 17 mg verpreßt werden.13.5 kg of colestyramine were in a pharmaceutical high-performance mixer (Lödige Druvatherm 50 l) with chopper with a solution of 0.7 kg poly vinyl pyrrolidone (average molecular weight 25,000) in 2.1 kg isopropanol offset and granulated. After drying in a rack dry cabinet at 50 ° C was over an oscillating sieve with 0.8 mm mesh sifted wide. The granules were highly dispersed in the pharmaceutical mixer with 70 g Silicon dioxide and 70 g magnesium stearate mixed. The ready-to-press mass could easily make micro-tablets with a diameter of 3 mm and the same height with a single mass of 17 mg.
Zur weiteren Verbesserung der Einnahme kann die erfindungsgemäße Mikro tablette zusätzlich nach bekannten Verfahren gecoatet werden, wobei man vorzugsweise wasserlösliche Cellulosederivate, wie z. B. Hydroxypropyl methylcellulose einsetzt.The micro according to the invention can be used to further improve the intake tablet can also be coated according to known methods, wherein one preferably water-soluble cellulose derivatives, such as. B. hydroxypropyl uses methyl cellulose.
Claims (3)
Priority Applications (13)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| DE3930168A DE3930168A1 (en) | 1989-09-09 | 1989-09-09 | Pharmaceutical compsn. contg. colestyramine to reduce lipid - in micro:tablet form levels without unpleasant taste |
| IL9557490A IL95574A (en) | 1989-09-09 | 1990-09-04 | Colestyramine preparation |
| DE59009451T DE59009451D1 (en) | 1989-09-09 | 1990-09-07 | PREPARATIONS CONTAINING COLESTYRAMINE AS A LIPID RECOVERER. |
| AT90913811T ATE125448T1 (en) | 1989-09-09 | 1990-09-07 | PREPARATIONS CONTAINING COLESTYRAMINE AS A LIPID LOWERING ANT. |
| ZA907130A ZA907130B (en) | 1989-09-09 | 1990-09-07 | Colestyramine as products containing lipid-lowering agents |
| MXPA92003517A MXPA92003517A (en) | 1989-09-09 | 1990-09-07 | Colestyramine as products containing lipid-lowering agents. |
| DK90913811.7T DK0594570T3 (en) | 1989-09-09 | 1990-09-07 | Colestyramine-containing micro tablets as lipid-lowering agent |
| PCT/EP1990/001514 WO1991003249A1 (en) | 1989-09-09 | 1990-09-07 | Preparations containing colestyramine for reducing lipid levels |
| CA002065151A CA2065151A1 (en) | 1989-09-09 | 1990-09-07 | Preparations containing colestyramine for reducing lipid levels |
| EP90913811A EP0594570B1 (en) | 1989-09-09 | 1990-09-07 | Preparations containing colestyramine for reducing lipid levels |
| KR1019920700526A KR920703071A (en) | 1989-09-09 | 1990-09-07 | Microtablets containing cholestyramine as lipid lowering agent |
| AU64057/90A AU638493B2 (en) | 1989-09-09 | 1990-09-07 | Preparations containing colestyramine for reducing lipid levels |
| JP2512849A JPH05500213A (en) | 1989-09-09 | 1990-09-07 | Preparations containing cholestyramine as a lipid-lowering agent |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| DE3930168A DE3930168A1 (en) | 1989-09-09 | 1989-09-09 | Pharmaceutical compsn. contg. colestyramine to reduce lipid - in micro:tablet form levels without unpleasant taste |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| DE3930168A1 true DE3930168A1 (en) | 1991-03-14 |
Family
ID=6389097
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| DE3930168A Withdrawn DE3930168A1 (en) | 1989-09-09 | 1989-09-09 | Pharmaceutical compsn. contg. colestyramine to reduce lipid - in micro:tablet form levels without unpleasant taste |
Country Status (3)
| Country | Link |
|---|---|
| DE (1) | DE3930168A1 (en) |
| MX (1) | MXPA92003517A (en) |
| ZA (1) | ZA907130B (en) |
Cited By (27)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2017138877A1 (en) * | 2016-02-09 | 2017-08-17 | Albireo Ab | Oral cholestyramine formulation and use thereof |
| WO2017138878A1 (en) * | 2016-02-09 | 2017-08-17 | Albireo Ab | Oral cholestyramine formulation and use thereof |
| US10000528B2 (en) | 2010-11-08 | 2018-06-19 | Albireo Ab | IBAT inhibitors for the treatment of liver diseases |
| US10183920B2 (en) | 2014-10-24 | 2019-01-22 | Elobix Ab | Crystal modifications of elobixibat |
| WO2019032026A1 (en) * | 2017-08-09 | 2019-02-14 | Albireo Ab | Cholestyramine granules, oral cholestyramine formulations and use thereof |
| WO2019032027A1 (en) * | 2017-08-09 | 2019-02-14 | Albireo Ab | Cholestyramine pellets, oral cholestyramine formulations and use thereof |
| US10441605B2 (en) | 2016-02-09 | 2019-10-15 | Albireo Ab | Oral cholestyramine formulation and use thereof |
| US10441604B2 (en) | 2016-02-09 | 2019-10-15 | Albireo Ab | Cholestyramine pellets and methods for preparation thereof |
| US10709755B2 (en) | 2014-06-25 | 2020-07-14 | Elobix Ab | Solid formulation and method for preventing or reducing coloration thereof |
| US10722457B2 (en) | 2018-08-09 | 2020-07-28 | Albireo Ab | Oral cholestyramine formulation and use thereof |
| US10786529B2 (en) | 2016-02-09 | 2020-09-29 | Albireo Ab | Oral cholestyramine formulation and use thereof |
| US10793534B2 (en) | 2018-06-05 | 2020-10-06 | Albireo Ab | Benzothia(di)azepine compounds and their use as bile acid modulators |
| US10941127B2 (en) | 2019-02-06 | 2021-03-09 | Albireo Ab | Benzothiadiazepine compounds and their use as bile acid modulators |
| US10975046B2 (en) | 2018-06-20 | 2021-04-13 | Albireo Ab | Crystal modifications of odevixibat |
| US10975045B2 (en) | 2019-02-06 | 2021-04-13 | Aibireo AB | Benzothiazepine compounds and their use as bile acid modulators |
| US11007142B2 (en) | 2018-08-09 | 2021-05-18 | Albireo Ab | Oral cholestyramine formulation and use thereof |
| US11014898B1 (en) | 2020-12-04 | 2021-05-25 | Albireo Ab | Benzothiazepine compounds and their use as bile acid modulators |
| US11111224B2 (en) | 2019-12-04 | 2021-09-07 | Albireo Ab | Benzothia(di)azepine compounds and their use as bile acid modulators |
| US11180465B2 (en) | 2019-12-04 | 2021-11-23 | Albireo Ab | Benzothia(di)azepine compounds and their use as bile acid modulators |
| US11225466B2 (en) | 2019-12-04 | 2022-01-18 | Albireo Ab | Benzothiadiazepine compounds and their use as bile acid modulators |
| US11267794B2 (en) | 2019-12-04 | 2022-03-08 | Albireo Ab | Benzothia(di)azepine compounds and their use as bile acid modulators |
| US11306064B2 (en) | 2018-06-05 | 2022-04-19 | Albireo Ab | Benzothia(di)azepine compounds and their use as bile acid modulators |
| US11377429B2 (en) | 2020-08-03 | 2022-07-05 | Albireo Ab | Benzothia(di)azepine compounds and their use as bile acid modulators |
| US11549878B2 (en) | 2018-08-09 | 2023-01-10 | Albireo Ab | In vitro method for determining the adsorbing capacity of an insoluble adsorbant |
| US11572350B1 (en) | 2020-12-04 | 2023-02-07 | Albireo Ab | Benzothia(di)azepine compounds and their use as bile acid modulators |
| US11583539B2 (en) | 2020-11-12 | 2023-02-21 | Albireo Ab | Treating progressive familial intrahepatic cholestasis (PFIC) with IBAT inhibitors |
| US11801226B2 (en) | 2018-06-20 | 2023-10-31 | Albireo Ab | Pharmaceutical formulation of odevixibat |
-
1989
- 1989-09-09 DE DE3930168A patent/DE3930168A1/en not_active Withdrawn
-
1990
- 1990-09-07 MX MXPA92003517A patent/MXPA92003517A/en unknown
- 1990-09-07 ZA ZA907130A patent/ZA907130B/en unknown
Cited By (54)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US10000528B2 (en) | 2010-11-08 | 2018-06-19 | Albireo Ab | IBAT inhibitors for the treatment of liver diseases |
| US10011633B2 (en) | 2010-11-08 | 2018-07-03 | Albireo Ab | IBAT inhibitors for the treatment of liver diseases |
| US10093697B2 (en) | 2010-11-08 | 2018-10-09 | Albireo Ab | IBAT inhibitors for the treatment of liver diseases |
| US11732006B2 (en) | 2010-11-08 | 2023-08-22 | Albireo Ab | IBAT inhibitors for the treatment of liver diseases |
| US10221212B2 (en) | 2010-11-08 | 2019-03-05 | Albireo Ab | IBAT inhibitors for the treatment of liver diseases |
| US10981952B2 (en) | 2010-11-08 | 2021-04-20 | Albireo Ab | IBAT inhibitors for the treatment of liver diseases |
| US11261212B2 (en) | 2010-11-08 | 2022-03-01 | Albireo Ab | IBAT inhibitors for the treatment of liver diseases |
| US10487111B2 (en) | 2010-11-08 | 2019-11-26 | Albireo Ab | IBAT inhibitors for the treatment of liver diseases |
| US11844822B2 (en) | 2014-06-25 | 2023-12-19 | Elobix Ab | Solid formulation and method for preventing or reducing coloration thereof |
| US10709755B2 (en) | 2014-06-25 | 2020-07-14 | Elobix Ab | Solid formulation and method for preventing or reducing coloration thereof |
| US10519120B2 (en) | 2014-10-24 | 2019-12-31 | Elobix Ab | Crystal modifications of elobixibat |
| US10183920B2 (en) | 2014-10-24 | 2019-01-22 | Elobix Ab | Crystal modifications of elobixibat |
| RU2750937C2 (en) * | 2016-02-09 | 2021-07-06 | Альбирео Аб | Oral cholestyramine composition and application thereof |
| US10493096B2 (en) | 2016-02-09 | 2019-12-03 | Albireo Ab | Oral cholestyramine formulation and use thereof |
| US10610543B2 (en) | 2016-02-09 | 2020-04-07 | Albireo Ab | Cholestyramine pellets and methods for preparation thereof |
| US10441604B2 (en) | 2016-02-09 | 2019-10-15 | Albireo Ab | Cholestyramine pellets and methods for preparation thereof |
| US10441605B2 (en) | 2016-02-09 | 2019-10-15 | Albireo Ab | Oral cholestyramine formulation and use thereof |
| RU2750944C2 (en) * | 2016-02-09 | 2021-07-06 | Альбирео Аб | Oral cholestyramine composition and application thereof |
| WO2017138878A1 (en) * | 2016-02-09 | 2017-08-17 | Albireo Ab | Oral cholestyramine formulation and use thereof |
| US10758563B2 (en) | 2016-02-09 | 2020-09-01 | Albireo Ab | Oral cholestyramine formulation and use thereof |
| US10786529B2 (en) | 2016-02-09 | 2020-09-29 | Albireo Ab | Oral cholestyramine formulation and use thereof |
| WO2017138877A1 (en) * | 2016-02-09 | 2017-08-17 | Albireo Ab | Oral cholestyramine formulation and use thereof |
| US10799527B2 (en) | 2016-02-09 | 2020-10-13 | Albireo Ab | Oral cholestyramine formulation and use thereof |
| US10864228B2 (en) | 2016-02-09 | 2020-12-15 | Albireo Ab | Oral cholestyramine formulation and use thereof |
| WO2019032027A1 (en) * | 2017-08-09 | 2019-02-14 | Albireo Ab | Cholestyramine pellets, oral cholestyramine formulations and use thereof |
| US10881685B2 (en) | 2017-08-09 | 2021-01-05 | Albireo Ab | Cholestyramine granules, oral cholestyramine formulations and use thereof |
| CN111032019B (en) * | 2017-08-09 | 2022-07-05 | 阿尔比里奥公司 | Cholestyramine granules, oral cholestyramine preparation and application thereof |
| CN110996915B (en) * | 2017-08-09 | 2023-10-03 | 阿尔比里奥公司 | Cholestyramine pellet, oral cholestyramine preparation and application thereof |
| CN111032019A (en) * | 2017-08-09 | 2020-04-17 | 阿尔比里奥公司 | Cholestyramine granules, oral cholestyramine preparation and application thereof |
| CN110996915A (en) * | 2017-08-09 | 2020-04-10 | 阿尔比里奥公司 | Colestyramine pellets, oral colestyramine formulations and uses thereof |
| WO2019032026A1 (en) * | 2017-08-09 | 2019-02-14 | Albireo Ab | Cholestyramine granules, oral cholestyramine formulations and use thereof |
| US11306064B2 (en) | 2018-06-05 | 2022-04-19 | Albireo Ab | Benzothia(di)azepine compounds and their use as bile acid modulators |
| US10793534B2 (en) | 2018-06-05 | 2020-10-06 | Albireo Ab | Benzothia(di)azepine compounds and their use as bile acid modulators |
| US10975046B2 (en) | 2018-06-20 | 2021-04-13 | Albireo Ab | Crystal modifications of odevixibat |
| US11801226B2 (en) | 2018-06-20 | 2023-10-31 | Albireo Ab | Pharmaceutical formulation of odevixibat |
| US11802115B2 (en) | 2018-06-20 | 2023-10-31 | Albireo Ab | Pharmaceutical formulation of odevixibat |
| US11365182B2 (en) | 2018-06-20 | 2022-06-21 | Albireo Ab | Crystal modifications of odevixibat |
| US10722457B2 (en) | 2018-08-09 | 2020-07-28 | Albireo Ab | Oral cholestyramine formulation and use thereof |
| US11007142B2 (en) | 2018-08-09 | 2021-05-18 | Albireo Ab | Oral cholestyramine formulation and use thereof |
| US11549878B2 (en) | 2018-08-09 | 2023-01-10 | Albireo Ab | In vitro method for determining the adsorbing capacity of an insoluble adsorbant |
| US10941127B2 (en) | 2019-02-06 | 2021-03-09 | Albireo Ab | Benzothiadiazepine compounds and their use as bile acid modulators |
| US10975045B2 (en) | 2019-02-06 | 2021-04-13 | Aibireo AB | Benzothiazepine compounds and their use as bile acid modulators |
| US11603359B2 (en) | 2019-02-06 | 2023-03-14 | Albireo Ab | Benzothiadiazepine compounds and their use as bile acid modulators |
| US11773071B2 (en) | 2019-02-06 | 2023-10-03 | Albireo Ab | Benzothiazepine compounds and their use as bile acid modulators |
| US11180465B2 (en) | 2019-12-04 | 2021-11-23 | Albireo Ab | Benzothia(di)azepine compounds and their use as bile acid modulators |
| US11891368B2 (en) | 2019-12-04 | 2024-02-06 | Albireo Ab | Benzothia(di)azepine compounds and their use as bile acid modulators |
| US11708340B2 (en) | 2019-12-04 | 2023-07-25 | Albireo Ab | Benzothia(di)azepine compounds and their use as bile acid modulators |
| US11111224B2 (en) | 2019-12-04 | 2021-09-07 | Albireo Ab | Benzothia(di)azepine compounds and their use as bile acid modulators |
| US11267794B2 (en) | 2019-12-04 | 2022-03-08 | Albireo Ab | Benzothia(di)azepine compounds and their use as bile acid modulators |
| US11225466B2 (en) | 2019-12-04 | 2022-01-18 | Albireo Ab | Benzothiadiazepine compounds and their use as bile acid modulators |
| US11377429B2 (en) | 2020-08-03 | 2022-07-05 | Albireo Ab | Benzothia(di)azepine compounds and their use as bile acid modulators |
| US11583539B2 (en) | 2020-11-12 | 2023-02-21 | Albireo Ab | Treating progressive familial intrahepatic cholestasis (PFIC) with IBAT inhibitors |
| US11014898B1 (en) | 2020-12-04 | 2021-05-25 | Albireo Ab | Benzothiazepine compounds and their use as bile acid modulators |
| US11572350B1 (en) | 2020-12-04 | 2023-02-07 | Albireo Ab | Benzothia(di)azepine compounds and their use as bile acid modulators |
Also Published As
| Publication number | Publication date |
|---|---|
| MXPA92003517A (en) | 2004-03-04 |
| ZA907130B (en) | 1992-05-27 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| DE3930168A1 (en) | Pharmaceutical compsn. contg. colestyramine to reduce lipid - in micro:tablet form levels without unpleasant taste | |
| EP0819429B1 (en) | Direct tabletting aid | |
| DE69434479T2 (en) | Tramadol-containing drug with controlled release of active ingredient | |
| DE69802543T3 (en) | IMPROVED MULTIPARTICLE TABLET WITH FAST RESOLUTION | |
| DE69920344T2 (en) | Use of an acrylic acid-type polymer as disintegrating agent, methods of making tablets and manufactured tablets | |
| DE2845326C2 (en) | Use of a specific microdisperse, amorphous, porous silica for the production of digoxin-containing tablets with a strongly accelerated release of active ingredient | |
| DE69826317T2 (en) | PROGESTERONTABLETTE AND METHOD FOR THE PRODUCTION THEREOF | |
| DE60304993T2 (en) | DISPERSIBLE PHARMACEUTICAL COMPOSITION WITH AGOMELATIN IN THE MOUTH VALVE | |
| DE69823360T2 (en) | SOLID MEDICAL CONSUMPTION CONTAINING BENZOFURANDERIVATE | |
| EP0594570B1 (en) | Preparations containing colestyramine for reducing lipid levels | |
| DE3505433A1 (en) | DIRECT TABLETING AIDS | |
| DE1279896B (en) | The use of an acidic copolymer for the production of tablets with prolonged drug release | |
| DE69814850T2 (en) | PARACETAMOL CONTAINING SLICKABLE TABLET | |
| DE2907215A1 (en) | SOLID DEPOT MEDICAL PREPARATIONS AND METHOD FOR THEIR MANUFACTURING | |
| DE60020501T2 (en) | Trimetazidine-containing matrix tablet for prolonged release of active ingredient after oral administration | |
| DE69530759T2 (en) | FILM COATED TABLET CONTAINING PARACETAMOL AND DOMPERIDONE | |
| DE60133028T2 (en) | MICROGRANULATE TO ACTIVE SUBSTANCE AND METHOD FOR THE PRODUCTION THEREOF | |
| DE69813872T2 (en) | COMPLEX OF CARRAGEENAN AND A WATER-SOLUBLE MEDICATION WITH A SPECIFIC GRANULOMETRY AND RELATED PHARMACEUTICAL COMPOSITIONS WITH CONTROLLED RELEASE | |
| DE2128461A1 (en) | Pharmaceutical preparation | |
| DE60103247T2 (en) | Process for the preparation of formulations for direct tabletting | |
| DE19758100B4 (en) | Process for the preparation of plant extract-containing pharmaceutical formulations | |
| EP0537139B1 (en) | Process for producing pressed, moulded, delayed release dose units and dose units thus produced | |
| EP1089739B1 (en) | Cyclophosphamide coated tablets | |
| DE602004005734T2 (en) | PHARMACEUTICAL COMPOSITION WITH CONTROLLED RELEASE AND METHOD FOR THE PRODUCTION THEREOF | |
| DE60111657T2 (en) | Pharmaceutical composition containing ibuprofen and a process for the preparation thereof |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| 8130 | Withdrawal |